Targeting the kidney and glucose excretion with dapagliflozin: Preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 135-148

  Whaley, Jean M ^a   Tirmenstein, Mark ^a   Reilly, Timothy P ^a   Poucher, Simon M ^b   Saye, Joanne ^b   Parikh, Shamik ^b   List, James F ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Dapagliflozin; Mechanism of action; SGLT2; Type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PHLORIZIN; PIOGLITAZONE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIDIABETIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BLOOD PRESSURE REGULATION; DIURESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY; KIDNEY DISEASE; LIVER TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TOXIC HEPATITIS; TREATMENT RESPONSE; URINARY EXCRETION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84872322553     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s22503     Document Type: Review

References (79)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
2. Nathan DM, Cleary PA, Backlund JY., et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
3. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
4. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443-453.
5. Eeg-Olofsson K, Cederholm J, Nilsson PM., et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1): 65-73.
6. Nathan DM, Buse JB, Davidson MB.et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
7. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463-478.
8. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9 Suppl 4: 326S-334S.
9. Handelsman Y, Mechanick JI, Blonde L, etal. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:S1-S53.
10. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45(7): 937-948.
11. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther. 2006;4(6):871-895.
12. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875-883.
13. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32-43.
14. Vallon V, Platt KA, Cunard R., et al. SGLT2mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1): 104-112.
15. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-794.
16. Grempler R, Augustin R, Froehner S., et al. Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett. 2011;586(3):248-253.
17. Chen J, William S, Ho S., et al. Quantitative PCR tissue expression profiling of the human SGLT2gene and related family members. Diabetes Ther. 2010;1(2):57-92.
18. Sabolic I, Vrhovac I, Balen ED., et al. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012. [Epub ahead of print.]
19. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1): 133-141.
20. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14(6):782-790.
21. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009;25(3): 671-681.
22. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971;28(1):101-109.
23. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2inhibitors in animals and humans. Kidney Int Suppl. 2011; 120:S20-S27.
24. Petersen C. Analyse des Phloridzins. Annales Académie Science Française. 1835;15:178. French.
25. Von Mering J. Ueber kunstlichen diabetes. Centralbl Med Wiss. 1886; 22:531. German.
26. Achard C, Delamare V. The bark of the apple root, phlorizin, reduces diabetic hyperglycemia. Soc Medic Des Hopitaux. 1899:379-393.
27. Chao EC, Henry RR. SGLT2inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-559.
28. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510-1515.
29. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80(4):1037-1044.
30. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992;263(3 Pt 2):F459-F465.
31. Washburn WN. Evolution of sodium glucose co-transporter 2inhibitors as anti-diabetic agents. Expert Opin Ther Pat. 2009;19(11):1485-1499.
32. Obermeier M, Yao M, Khanna A, etal. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-414.
33. Han S, Hagan DL, Taylor JR, etal. Dapagliflozin, a selective SGLT2inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723-1729.
34. Uveges A, Hagan D, Onorato J., et al. Dapagliflozin selectively inhibits human SGLT2 versus SGLT1, SMIT1, SGLT4, and SGLT6. Presented at the American Diabetes Association 71st Scientific Sessions; June 24-28, 2011. San Diego, CA: 2011:Poster P-987.
35. Poucher SM, DeSchoolmeester J, Ehenborn J, Vernon W, Clementz T. Dapagliflozin selectivity for glucose transporters GLUT1, 2, and 4. Presented at the American Diabetes Association 71st Scientific Sessions; June 24-28, 2011. San Diego, CA: Poster P-1041.
36. Bristol Myers-Squibb, AstraZeneca. US Food and Drug Administration Endocrinologic and Metabolic Advisory Committee background document: dapagliflozin, BMS-512148, NDA 202293. US Food and Drug Administration. Available from: www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262993.htm. Accessed July 20, 2011.
37. Devenny J, Harvey S, Rooney S., et al. The effect of dapagliflozin, a highly selective SGLT-2inhibitor on body weight in diet-induced obese rats. Obesity. 2007;15(Suppl 19):A121.
38. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513-519.
39. Salsali A, Hruba V, Ying L., et al. Reduction in postprandial glucose with dapagliflozin in type 2 diabetes [abstract]. Diabetes. 2011; 60:A286:1104-P.
40. Gerich JE. Physiology of glucose homeostasis. Diabetes Obes Metab. 2000;2(6):345-350.
41. Kasichayanula S, Liu X, Pe Benito M, LaCreta F, Boulton DW. Influence of renal function on dapagliflozin pharmacodynamics in patients with type 2 diabetes mellitus [abstract]. Presented at the American Society of Nephrology; November 8-13, 2011. Philadephia, PA: 2011:TH-PO525.
42. Zinker B, Ma X, Liu H., et al. Chronic dapagliflozin treatment reduces elevated hepatic glucose production and enhances pancreatic insulin content in male ZDF rats [abstract]. Diabetes. 2011;60:A283:1031-P.
43. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217-2224.
44. Henry R, Murray A, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin-XR, or both together as initial therapy for T2DM [abstract]. Diabetes. 2011;60:A84:307-OR.
45. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.
46. Rosenstock J, Vico M, Wei L, Salsali A, List J. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes [abstract]. Diabetes. 2011; 60:A270:986-P.
47. Strojek K, Yoon KH, Hruba B, Elze M, Langkilde AM. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-938.
48. Wilding JP, Woo V, Soler NG., et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405-415.
49. Bailey CJ, Gross JL, Yadav M, Iqbal N, Mansfield TA, List JF. Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone [abstract]. Diabetes. 2011;60: A271:988-P.
50. Woo V, Tang W, Salsali A, List JF. Long-term efficacy of dapagliflozin monotherapy in patients with type 2 diabetes mellitus [abstract]. Presented at the International Diabetes Federation World Diabetes Congress; December 4-8, 2011. Dubai, United Arab Emirates: 2011:D-0991.
51. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Presented at the American Diabetes Association 71st Scientific Sessions; June 24-28, 2011. San Diego, CA: 2011:40-LB.
52. Bavenholm PN, Efendic S. Postprandial hyperglycaemia and vascular damage - the benefits of acarbose. Diab Vasc Dis Res. 2006;3(2): 72-79.
53. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-657.
54. Kohan DE, Fioretto P, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract]. J Am Soc Nephrol. 2011;Suppl:22:TH-PO524.
55. Zinker B, Ma X, Liu H, Washburn W, Whaley J. Acute glucose fluxes following a single dose of dapagliflozin [abstract]. Diabetes. 2011;60: A273:995-P.
56. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Long-term efficacy of dapagliflozin as add-on to metformin in T2DM inadequately controlled with metformin alone. Presented at the American Diabetes Association 71st Scientific Sessions; June 24-28, 2011. San Diego, CA: 2011:988-P.
57. Wilding JPH, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin [abstract]. Diabetes. 2010;59:LB7. Abstract 21-LB.
58. Nauck MA, Del Prato S, Meier JJ., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9): 2015-2022.
59. Bolinder J, Ljunggren O, Kullberg J., et al. Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012. [Epub ahead of print.]
60. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3-19.
61. Macdonald FR, Peel JE, Jones HB., et al. The novel SGLT2inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12(11): 1004-1012.
62. Jurczak MJ, Lee HY, Birkenfeld AL., et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890-898.
63. Salsali A, Bastien A, Mansfield T, Ying L, Ravichandran S, List JF. Dapagliflozin improves hyperglycemia and beta-cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus [abstract]. Presented at the American Association of Clinical Endocrinologists; April 13-17, 2011. San Diego, CA: 2011:204.
64. Mudaliar S, Henry R, Boden G., et al. Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter 2inhibitor dapagliflozin. Presented at the 47th Annual Meeting of the European Association for the Study of Diabetes; September 12-16, 2011. Lisbon, Portugal: 2011: Abstract 854.
65. Lang F. Osmotic diuresis. Ren Physiol. 1987;10(3/4):160-173.
66. Heerspink HJ, List J, Boulton D, Liu X, Ying L, deZeeuw D. The SGLT2inhibitor dapagliflozin, a proximal tubular diuretic with antihypertensive properties? Presented at the World Congress of Nephrology 2011; April 8-12, 2011. Vancouver, Canada: 2011:Abstract SU183.
67. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656-1662.
68. Wilcox CS, Liu X, Kasichayanula S., et al. Evaluation of interactions of dapagliflozin and bumetanide. Presented at the American Society of Nephrology; November 16-21, 2010. Denver, CO: 2010.
69. Thomson SC, Miracle C, Rieg T, Whaley J, Vallon V. Chronic SGLT2 blockade reduces proximal reabsorption and normalizes state of tubuloglomerular feedback activation in hyperfiltering diabetic rats [abstract]. J Am Soc Nephrol. 2009;20:734A:2723.
70. Kutina AV, Zakharov VV, Natochin YV. Excretion of proteins by rat kidney during various types of diuresis. Bull Exp Biol Med. 2008; 146(6):671-674.
71. Lina BA, Bos-Kuijpers MH, Til HP, Bar A. Chronic toxicity and carcinogenicity study of erythritol in rats. Regul Toxicol Pharmacol. 1996;24(2 Pt 2):S264-S279.
72. Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List JF. Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes. 2011;60: A270:984-P.
73. List JF, Ley S, Ptaszynska A., et al. Characterization of genital infections in the setting of pharmacologically-induced glucosuria [abstract]. Diabetes. 2011;60:A270:985-P.
74. Campbell JM, Fahey GC Jr, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr. 1997;127(1):130-136.
75. Kasahara M, Maeda M, Hayashi S, Mori Y, Abe T. A missense mutation in the Na(+)/glucose cotransporter gene SGLT1in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein. Biochim Biophys Acta. 2001; 1536(2/3):141-147.
76. Wright EM. Genetic disorders of membrane transport. I. Gluocse galactose malabsorption. Gastrointest Liver Physiol. 1998;275(5):G879-G882.
77. Zafar TA, Weaver CM, Zhao Y, Martin BR, Wastney ME. Nondigestible oligosaccharides increase calcium absorption and suppress bone resorption in ovariectomized rats. J Nutr. 2004;134(2):399-402.
78. Wilding JPH, Woo V, Soler NG, et al. Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy-efficacy of a novel insulin-independent treatment [abstract]. Diabetes. 2010;59:A21-A22:78-OR.
79. Strojek K, Hruba V, Elze M, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy. Diabetologia. 2010;53:S347:870-P.